Clinical trials: Neoadjuvant Treatment
Gastric Adenocarcinoma
SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer
This is a randomized, multicenter, controlled trial to prove efficacy of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Advanced Gastric Cancer Patients who undergo D2 gastrectomy.
- Trial name
- RESONANCE (NCT01583361)
- Testing
- Oxaliplatin+S-1, Adjuvant Oxaliplatin/S-1（SOX）
- Where
- China
- Volunteers
- 772 people
- Sponsor
- Lin Chen
Esophageal Cancer, Esophageal Adenocarcinoma
Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer
Rationale: For locally advanced esophageal cancer the standard treatment consists of 5 weeks of neoadjuvant chemoradiotherapy (nCRT) followed by surgery.
- Conditions
- Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms
- Trial name
- PRIDE (NCT03474341)
- Testing
- MRI, PET-CT, Endoscopy
- Where
- 4 sites in Netherlands
- Volunteers
- 200 people
- Sponsor
- UMC Utrecht
Locally Advanced Rectal Cancer, Neoadjuvant Therapy
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
TORCH-iTNT is a prospective, multicentre, randomized phase II trial. 198 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with total neoadjuvant therapy (TNT) and assigned to Group A and Group B (1:1).
- Trial name
- TORCH-iTNT (NCT06281405)
- Testing
- PD-1 inhibitor, Capecitabine, Short-course radiotherapy
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Fudan University
Head and Neck Cancers
A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) refers to a series of tumors that occur in the head and neck region, including the oral cavity, pharynx, larynx, nasal cavity, paranasal sinuses, thyroid gland, and salivary glands.
- Trial name
- NCT06894459
- Testing
- Pembrolizumab, Cisplatin, Nab-paclitaxel
- Volunteers
- 180 people
- Sponsor
- Beijing Tongren Hospital
Esophageal Squamous Cell Carcinoma Stage cT3-4aN0-1M0
Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCC
The purpose of this study is to evaluate the outcomes of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy on patients with locally advanced resectable esophageal squamous…
- Trial name
- ESCCNCRTvNCT (NCT03001596)
- Testing
- Neoadjuvant Chemoradiotherapy, Neoadjuvant Chemotherapy, Minimally Invasive Esophagectomy
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Shanghai Zhongshan Hospital
Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin
Intratumoral PH-762 for Cutaneous Carcinoma
The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the…
- Conditions
- Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin, Merkel Cell Carcinoma of Skin
- Trial name
- NCT06014086
- Testing
- PH-762
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Phio Pharmaceuticals Inc.
Breast Neoplasms
Biomarkers Investigation of Neoadjuvant Chemotherapy for Breast Cancer
The BINC-B trial is a diagnostic and interventional study in which various function imaging methods as Magnetic Resonance Imaging (PWI, DWI and DCE-MRI) and will be compared with common imaging methods (mammography and/or…
- Trial name
- BINC-B (NCT03242551)
- Testing
- Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Shenzhen People's Hospital
Stage II Esophageal Cancer, Stage III Esophageal Cancer
A Study to Compare Efficacy and Safety of DRT VS CRT Plus Surgery in Patients Who Achieved CCR for Esophageal Cancer
Neoadjuvant chemoradiotherapy(Neo-CRT) plus surgery has been regarded as a standard of care for patients with resectable locally advanced esophageal cancer.
- Trial name
- NCT03708042
- Testing
- Definitive Radiochemotherapy, Neoadjuvant Radiochemotherapy
- Volunteers
- 220 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
Intravenous Ascorbic Acid Supplementation in Neoadjuvant Chemotherapy for Breast Cancer
Forty years ago clinical studies conducted by Ewan Cameron and Linus Pauling suggested that intravenous (IV) and oral ascorbic acid (AA) may diminish symptoms and could improve survival in terminal cancer patients.
- Trial name
- NCT03175341
- Testing
- Ascorbic Acid
- Where
- Romania
- Volunteers
- 30 people
- Sponsor
- Academic Emergency County Hospital Sibiu
Prostate Cancer With ≤10 Bone Metastases
Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases
The aim of this study is to evaluate the efficacy and safety of apalutamide in combination with 89Sr as neoadjuvant therapy in prostate cancer with ≤10 bone metastases.
- Trial name
- NCT05740488
- Testing
- Apalutamide, 89Sr, Luteinizing Hormone-Releasing Hormone Analog
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhujiang Hospital
Breast Cancer
Supervised Exercise to Promote Infiltration of NK-cells Into the Tumor
'Supervised exercise to PRomote Infiltration of NK-cells into the Tumor? The objective of this feasibility study is to 1) study trial feasibility in terms of patient enrollment and the percentage of tumor biopsies that can be…
- Trial name
- SPRINT (NCT04704856)
- Testing
- Supervised exercise
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- Amsterdam UMC, location VUmc
Breast Cancer
A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer
To study the maximum tolerated dose of Doxorubicin Hydrochloride Liposome Injection combination with cyclophosphamide and sequential treatment of docetaxel for patients with locally advanced breast cancer
- Trial name
- NCT03017404
- Testing
- Doxorubicin Hydrochloride Liposome Injection, Cyclophosphamide, docetaxel
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hebei Medical University Fourth Hospital
ALK, NSCLC
Neoadjuvant Iruplinalkib and Bevacizumab in ALK-positive NSCLC: A Phase II Single-arm Trial
This is a single-center, single-arm, prospective phase II trial evaluating iruplinalkib plus bevacizumab as neoadjuvant therapy in ALK-positive NSCLC.
- Conditions
- ALK, NSCLC, Neoadjuvant Therapy
- Trial name
- NCT07870733
- Testing
- Bevacizumab combined with iruplinalkib as neoadjuvant therapy in ALK-positive NSCLC:
- Volunteers
- 40 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Melanoma
Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma
This is an open label, single centre, phase II study of neoadjuvant drug treatment with dabrafenib + trametinib in patients with resectable American Joint Committee on Cancer (AJCC) Stage IIIB-C BRAF V600 mutation positive…
- Trial name
- Neo Combi (NCT01972347)
- Testing
- Dabrafenib, Trametinib
- Where
- Australia
- Volunteers
- 35 people
- Sponsor
- Melanoma Institute Australia
Ovarian Cancer, Fallopian Tube Cancer
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
This study is a randomized, open-label, multi-cohort, multicenter clinical trial, aimed at evaluating the efficacy and safety of Fluzoparib monotherapy, Fluzoparib in combination with Bevacizumab, and standard chemotherapy…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT06735326
- Testing
- Fluzoparib, Bevacizumab, Paclitaxel
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Qilu Hospital of Shandong University
Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
This study is a randomized, open-label Phase 2 study to compare the efficacy and safety of IBI363 Combined with Chemotherapy or Pembrolizumab Combined with Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III…
- Trial name
- NCT07122687
- Testing
- Pemetrexed, Cisplatin, IBI363
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Non-small-Cell Lung Carcinoma
Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer
The primary objective of this study is to assess the response rate of treatment with two cycles of cisplatin and docetaxel chemotherapy prior to surgery (neoadjuvant) for early stage non-small cell lung cancer (NSCLC).
- Trial name
- NCT00232206
- Testing
- Neoadjuvant Therapy with Cisplatin Plus Docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Providence Health & Services
Refractory/Relapse Acute Myeloid Leukemia
Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia
This study aims to assess the therapeutic efficacy and safety of venetoclax in combination with azacitidine and CAG as induction regimen in Patients with Refreactory/Relapse Acute Myeloid Leukemia.
- Trial name
- NCT05807347
- Testing
- Venetoclax
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Hematology department of the 920th hospital
Esophageal Cancer
dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction Chemoimmunotherapy
This study is evaluating two treatment approaches for patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC) who have a good response to 2-3 cycles of induction chemoimmunotherapy.
- Trial name
- SORT (NCT07162506)
- Testing
- Surgery, Radiotherapy, Chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Mantle Cell Lymphoma
CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma
First-line CAR-T-cell consolidation after an abbreviated induction with 2 cycles of Rituximab and Ibrutinib prior to CAR-T-cell treatment and followed by 6 months of maintenance with Ibrutinib in patients with high risk MCL.
- Trial name
- CARMAN (NCT06482684)
- Testing
- KTE-X19, Ibrutinib
- Where
- 2 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Christian Schmidt, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.